Inventor profile of:

John Fraser Wright

City:

Princeton, New Jersey

Country:

United States

Published Applications:

17

Last publication date:

2020-09-24

Top Assignees for applications by John Fraser Wright

The entities that hold a legal rights for patent applications filed by inventor Wright John Fraser:

Recent patent applications by Wright John Fraser

John Fraser Wright from Princeton, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2020-09-24
US20200299650A1
Chemistry; metallurgy

Column-based fully scalable rAAV manufacturing process

#2 | 2020-05-28
US20200165632A1
Chemistry; metallurgy

ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION

#3 | 2020-05-28
US20200164008A1
Human necessities

APHERESIS METHODS AND USES

#4 | 2019-10-24
US20190321463A1
Human necessities

SCALABLE MANUFACTURING PLATFORM FOR VIRAL VECTOR PURIFICATION AND VIRAL VECTORS SO PURIFIED FOR USE IN GENE THERAPY

#5 | 2019-09-26
US20190292561A1
Chemistry; metallurgy

SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE

#6 | 2019-09-19
US20190284576A1
Chemistry; metallurgy

SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBY

#7 | 2019-03-28
US20190093126A1
Chemistry; metallurgy

Large commercial scale lentiviral vector production system and vectors produced thereby

#8 | 2019-03-14
US20190078099A1
Chemistry; metallurgy

CELL LINE FOR RECOMBINANT PROTEIN AND/OR VIRAL VECTOR PRODUCTION

#9 | 2018-05-17
US20180135097A1
Chemistry; metallurgy

Rab Escort Protein potency assay

#10 | 2017-12-28
US20170368201A1
Human necessities

Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system

#11 | 2017-05-11
US20170128594A1
Human necessities

Humanized viral vectors and methods of use thereof

#12 | 2016-07-21
US20160206706A1
Human necessities

Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy

#13 | 2014-02-06
US20140037585A1
Chemistry; metallurgy

AAV8 vector with enhanced functional activity and methods of use thereof

#14 | 2013-03-21
US20130072548A1
Chemistry; metallurgy

Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy

#15 | 2011-03-31
US20110076744A1
Chemistry; metallurgy

Compositions and methods to prevent AAV vector aggregation

#16 | 2010-04-22
US20100098666A1
Chemistry; metallurgy

Humanized Viral Vectors and Methods of Use Thereof

#17 | 2006-02-16
US20060035364A1
Chemistry; metallurgy

Compositions and methods to prevent AAV vector aggregation

InventorID:

154532 ⎘